Literature DB >> 27852113

Cancer nanomedicines: oversold or underappreciated?

Roy van der Meel1,2, Twan Lammers3,4,5, Wim E Hennink5.   

Abstract

Entities:  

Keywords:  Cancer nanomedicines; Clinical translation; Clinical trials; Combination treatment; Drug delivery; Drug targeting; EPR effect; Triggered release

Year:  2016        PMID： 27852113      PMCID： PMC5404718          DOI： 10.1080/17425247.2017.1262346

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN： 1742-5247            Impact factor:   6.648


× No keyword cloud information.
  14 in total

1.  Lessons in simplicity that should shape the future of drug delivery.

Authors:  Koen Raemdonck; Stefaan C De Smedt
Journal:  Nat Biotechnol       Date:  2015-10       Impact factor: 54.908

Review 2.  Analysis on the current status of targeted drug delivery to tumors.

Authors:  Il Keun Kwon; Sang Cheon Lee; Bumsoo Han; Kinam Park
Journal:  J Control Release       Date:  2012-07-16       Impact factor: 9.776

3.  Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes.

Authors:  K J Harrington; S Mohammadtaghi; P S Uster; D Glass; A M Peters; R G Vile; J S Stewart
Journal:  Clin Cancer Res       Date:  2001-02       Impact factor: 12.531

Review 4.  Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.

Authors:  Roy van der Meel; Laurens J C Vehmeijer; Robbert J Kok; Gert Storm; Ethlinn V B van Gaal
Journal:  Adv Drug Deliv Rev       Date:  2013-09-06       Impact factor: 15.470

Review 5.  Challenges and strategies in anti-cancer nanomedicine development: An industry perspective.

Authors:  Jennifer I Hare; Twan Lammers; Marianne B Ashford; Sanyogitta Puri; Gert Storm; Simon T Barry
Journal:  Adv Drug Deliv Rev       Date:  2016-04-29       Impact factor: 15.470

6.  Gulp1 is associated with the pharmacokinetics of PEGylated liposomal doxorubicin (PLD) in inbred mouse strains.

Authors:  Gina Song; Oscar T Suzuki; Charlene M Santos; Andrew T Lucas; Tim Wiltshire; William C Zamboni
Journal:  Nanomedicine       Date:  2016-06-09       Impact factor: 5.307

7.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.

Authors:  Y Matsumura; H Maeda
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

8.  Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth in vivo.

Authors:  Jan Kroon; Jeroen T Buijs; Geertje van der Horst; Henry Cheung; Maaike van der Mark; Louis van Bloois; Larissa Y Rizzo; Twan Lammers; Rob C Pelger; Gert Storm; Gabri van der Pluijm; Josbert M Metselaar
Journal:  Prostate       Date:  2015-02-08       Impact factor: 4.104

9.  Cancer nanomedicine: Is targeting our target?

Authors:  Twan Lammers; Fabian Kiessling; Marianne Ashford; Wim Hennink; Daan Crommelin; Gert Storm
Journal:  Nat Rev Mater       Date:  2016-09-07       Impact factor: 66.308

Review 10.  Extracellular vesicles as drug delivery systems: lessons from the liposome field.

Authors:  Roy van der Meel; Marcel H A M Fens; Pieter Vader; Wouter W van Solinge; Omolola Eniola-Adefeso; Raymond M Schiffelers
Journal:  J Control Release       Date:  2014-08-02       Impact factor: 9.776
View more
  28 in total

Review 1.  Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies.

Authors:  Frederik Soetaert; Preethi Korangath; David Serantes; Steven Fiering; Robert Ivkov
Journal:  Adv Drug Deliv Rev       Date:  2020-06-27       Impact factor: 15.470

Review 2.  Applying nanomedicine in maladaptive inflammation and angiogenesis.

Authors:  Amr Alaarg; Carlos Pérez-Medina; Josbert M Metselaar; Matthias Nahrendorf; Zahi A Fayad; Gert Storm; Willem J M Mulder
Journal:  Adv Drug Deliv Rev       Date:  2017-05-12       Impact factor: 15.470

3.  Smart cancer nanomedicine.

Authors:  Roy van der Meel; Einar Sulheim; Yang Shi; Fabian Kiessling; Willem J M Mulder; Twan Lammers
Journal:  Nat Nanotechnol       Date:  2019-11-06       Impact factor: 39.213

4.  Target-or-Clear Zirconium-89 Labeled Silica Nanoparticles for Enhanced Cancer-Directed Uptake in Melanoma: A Comparison of Radiolabeling Strategies.

Authors:  Feng Chen; Kai Ma; Li Zhang; Brian Madajewski; Pat Zanzonico; Sonia Sequeira; Mithat Gonen; Ulrich Wiesner; Michelle S Bradbury
Journal:  Chem Mater       Date:  2017-09-06       Impact factor: 9.811

Review 5.  Nanoscale artificial antigen presenting cells for cancer immunotherapy.

Authors:  Kelly R Rhodes; Jordan J Green
Journal:  Mol Immunol       Date:  2018-03-07       Impact factor: 4.407

Review 6.  Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?

Authors:  María Vallet-Regí; Ferdi Schüth; Daniel Lozano; Montserrat Colilla; Miguel Manzano
Journal:  Chem Soc Rev       Date:  2022-07-04       Impact factor: 60.615

7.  Targeted inhibition of human hematological cancers in vivo by doxorubicin encapsulated in smart lipoic acid-crosslinked hyaluronic acid nanoparticles.

Authors:  Yinan Zhong; Fenghua Meng; Chao Deng; Xinliang Mao; Zhiyuan Zhong
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

Review 8.  Targeted Therapeutic Nanoparticles: An Immense Promise to Fight against Cancer.

Authors:  Sheikh Tasnim Jahan; Sams M A Sadat; Matthew Walliser; Azita Haddadi
Journal:  J Drug Deliv       Date:  2017-12-31

Review 9.  Plasma medicine: Opportunities for nanotechnology in a digital age.

Authors:  Dawei Liu; Endre J Szili; Kostya Ken Ostrikov
Journal:  Plasma Process Polym       Date:  2020-07-09       Impact factor: 3.877

10.  Different Nanoformulations Alter the Tissue Distribution of Paclitaxel, Which Aligns with Reported Distinct Efficacy and Safety Profiles.

Authors:  Feng Li; Huixia Zhang; Miao He; Jinhui Liao; Nianhang Chen; Yan Li; Simon Zhou; Maria Palmisano; Alex Yu; Manjunath P Pai; Hebao Yuan; Duxin Sun
Journal:  Mol Pharm       Date:  2018-09-21       Impact factor: 4.939
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.